HUP0301915A3 - Use of sildenafil and other compounds with pde5 activity for the preparation of pharmaceutical composition treating premature ejaculation - Google Patents

Use of sildenafil and other compounds with pde5 activity for the preparation of pharmaceutical composition treating premature ejaculation

Info

Publication number
HUP0301915A3
HUP0301915A3 HU0301915A HUP0301915A HUP0301915A3 HU P0301915 A3 HUP0301915 A3 HU P0301915A3 HU 0301915 A HU0301915 A HU 0301915A HU P0301915 A HUP0301915 A HU P0301915A HU P0301915 A3 HUP0301915 A3 HU P0301915A3
Authority
HU
Hungary
Prior art keywords
sildenafil
compounds
preparation
pharmaceutical composition
premature ejaculation
Prior art date
Application number
HU0301915A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HUP0301915A2 publication Critical patent/HUP0301915A2/hu
Publication of HUP0301915A3 publication Critical patent/HUP0301915A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0301915A 2000-11-20 2001-11-19 Use of sildenafil and other compounds with pde5 activity for the preparation of pharmaceutical composition treating premature ejaculation HUP0301915A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028245.9A GB0028245D0 (en) 2000-11-20 2000-11-20 New therapeutic use
PCT/IB2001/002180 WO2002040027A1 (en) 2000-11-20 2001-11-19 Treatment of premature ejaculation

Publications (2)

Publication Number Publication Date
HUP0301915A2 HUP0301915A2 (hu) 2003-09-29
HUP0301915A3 true HUP0301915A3 (en) 2007-03-28

Family

ID=9903491

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301915A HUP0301915A3 (en) 2000-11-20 2001-11-19 Use of sildenafil and other compounds with pde5 activity for the preparation of pharmaceutical composition treating premature ejaculation

Country Status (21)

Country Link
EP (1) EP1335730B1 (https=)
JP (1) JP2004520279A (https=)
KR (1) KR100595807B1 (https=)
CN (1) CN1474692A (https=)
AT (1) ATE296631T1 (https=)
AU (2) AU2002215149B2 (https=)
BR (1) BR0115413A (https=)
CA (1) CA2429114C (https=)
DE (1) DE60111254T2 (https=)
ES (1) ES2240537T3 (https=)
GB (1) GB0028245D0 (https=)
HU (1) HUP0301915A3 (https=)
IL (1) IL155521A0 (https=)
MX (1) MXPA03003586A (https=)
MY (1) MY131573A (https=)
NZ (1) NZ525167A (https=)
PL (1) PL362058A1 (https=)
PT (1) PT1335730E (https=)
TW (1) TWI280132B (https=)
WO (1) WO2002040027A1 (https=)
ZA (1) ZA200302947B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)
CN111297869A (zh) * 2020-04-23 2020-06-19 白文智 一种用于治疗早泄和勃起功能障碍的复方制剂

Also Published As

Publication number Publication date
DE60111254D1 (de) 2005-07-07
AU1514902A (en) 2002-05-27
EP1335730B1 (en) 2005-06-01
GB0028245D0 (en) 2001-01-03
ATE296631T1 (de) 2005-06-15
IL155521A0 (en) 2003-11-23
NZ525167A (en) 2005-02-25
BR0115413A (pt) 2003-10-07
JP2004520279A (ja) 2004-07-08
WO2002040027A1 (en) 2002-05-23
KR100595807B1 (ko) 2006-07-03
MXPA03003586A (es) 2003-07-14
PT1335730E (pt) 2005-09-30
PL362058A1 (en) 2004-10-18
CN1474692A (zh) 2004-02-11
CA2429114C (en) 2007-09-11
DE60111254T2 (de) 2006-05-04
TWI280132B (en) 2007-05-01
HUP0301915A2 (hu) 2003-09-29
CA2429114A1 (en) 2002-05-23
KR20030048476A (ko) 2003-06-19
EP1335730A1 (en) 2003-08-20
ES2240537T3 (es) 2005-10-16
AU2002215149B2 (en) 2006-04-06
ZA200302947B (en) 2004-04-28
MY131573A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
EG24408A (en) Low dose entecavir formulation and use
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
IL183512A (en) Annals of 5-Amino-2-Oxo-Thiazolo [d-5,4] Pyrimidine-3 (or 2) Ill- Tetrahydroporan, Containing and Using Pharmaceutical Preparations
IL219669A0 (en) PYRAZOLO [1,5-a]PYRIDINES AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
PL393259A1 (pl) Mimetyki trombopoetyny, kompozycje farmaceutyczne je zawierające, zastosowanie tych związków do wytwarzania leków, sposoby wytwarzania związków, kompozycji, sposób poprawy stymulacji dojrzewania megakariocytów, sposób poprawy przeżywalności i/lub proliferacji komórek oraz związki pośrednie
IL158499A (en) Malononitrile compounds and their use in the manufacture of pesticide compositions
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
PL367093A1 (en) Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
HUP0303566A3 (en) Pharmaceutical composition containing combination of fenofibrate and coenzyme q10 and its use for the treatment of endothelial dysfunction
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
HUP0500328A3 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
HUP0301915A3 (en) Use of sildenafil and other compounds with pde5 activity for the preparation of pharmaceutical composition treating premature ejaculation
HUP0402062A3 (en) Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
IL148907A0 (en) Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
HUP0303910A3 (en) Use of kapp-opiate agonists for preparation of pharmaceutical composition for the treatment of bladder dieseases

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees